Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma

SIMPLE SUMMARY: Immune checkpoint inhibitor (ICI) therapy has recently become the standard treatment for advanced hepatocellular carcinoma (HCC); however, clinical outcomes remain unsatisfactory. Locoregional therapies, such as ablation, transarterial embolization, and radiotherapy, which are usuall...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamai, Yasuyuki, Fujiwara, Naoto, Tanaka, Takamitsu, Mizuno, Shugo, Nakagawa, Hayato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605879/
https://www.ncbi.nlm.nih.gov/pubmed/37894439
http://dx.doi.org/10.3390/cancers15205072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605879/
https://www.ncbi.nlm.nih.gov/pubmed/37894439
http://dx.doi.org/10.3390/cancers15205072

Ejemplares similares